Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1997-12-24
2001-07-10
Richter, Johann (Department: 1613)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S135000, C548S463000, C548S525000, C549S060000, C549S289000, C549S472000
Reexamination Certificate
active
06258839
ABSTRACT:
TECHNICAL FIELD OF THE INVENTION
The present invention relates to the extraction and purification of a dihydo-isoflavonone from the stem bark, the root and the leaves of
Bolusanthus speciosus
(Bolus) Harms belonging to the plant family Fabaceae: Fabiodeae; identification of the structure of the dihydro-isoflavonone isolated to the potential clinical applications of the pure dihydo-isoflavonone as anti-HIV and anti-cancer chemotherapeutic compound among other applications still under evaluation.
BACKGROUND TO THE INVENTION
Largely as a result of AIDS pandemic which is particularly evident in Africa, palliatives and/or cures have been sought by all research groups world wide. In Africa and more particularly in Zimbabwe, the Zimbabwe National Traditional Healers Association (ZINATHA) and local scientists have long believed that naturally occurring substances extracted from various medicinal plants have the required properties to the control and/or provide cures of HIV, cancers and other diseases.
To further their belief, ZINATHA entered into an agreement on Nov. 22, 1992 with the Developmental Therapeutics Program (DTP) Division of Cancer Treatment (DCT) of the National Cancer Institute (NCI) of the United States of America, whereby ZINATHA and NCI would collaborate in the evaluation of medicinal and other Zimbabwean plants and ZINATHA would supply to NCI such plant specimens and extracts as ZINATHA considered likely to have and/or contain active principles which could be extracted for structural elucidation and for clinical trials. Following upon this agreement, one Peter M. Mashava, (Ph.D.) of the University of Zimbabwe, undertook the task of investigating certain preferred specimens, notably
B. speciosus.
Using standard procedures, he isolated an active principle which he designated as “PMZ-1”.
SUMMARY OF THE INVENTION
The invention relates to a method of treating cancer or HIV by administering an effective dosage of a dihydro-isoflavonone to a mammal infected with HIV or for treatment of symptoms of acquired immuno deficiency syndrome or cancer.
REFERENCES:
Maillard et al., An Antifungal Isoflavanone and a Structure Rev. of a Flavonone from Erythrina, Planta Med. 55(3), 281-282, 1989.
Norris Jerome J.
Richter Johann
Solola Taofiq A.
LandOfFree
Isolation of naturally occuring isoflavanone and some... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isolation of naturally occuring isoflavanone and some..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isolation of naturally occuring isoflavanone and some... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2492367